Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of FGFR Inhibitor Futibatinib in Combination With Anti-PD-1 Antibody Pembrolizumab in Patients With Advanced or Metastatic Hepatocellular Carcinoma With FGF19 Expression After First Line Therapy

NCT04828486 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT04828486
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04828486 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of FGFR Inhibitor Futibatinib in Combination With Anti-PD-1 Antibody Pembrolizumab in Patients With Advanced or Metastatic Hepatocellular Carcinoma With FGF19 Expression After First Line Therapy
Lead sponsor
Mayo Clinic
Phase
Phase 2
Overall status
Completed
Start date
August 17, 2021
Completion date
August 31, 2025
Enrollment
14 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced hepatocellular carcinoma, bclc stage a hepatocellular carcinoma, bclc stage b hepatocellular carcinoma, bclc stage c hepatocellular carcinoma, metastatic hepatocellular carcinoma